Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway

Feng, Ying; Zhu, Bin; Liu, Yao; Zhou, Guiqin; Yang, Li; Liu, Long; Ren, Jie; Hou, Yixin; Yu, Honggang; Meng, Peipei; Jiang, Yuyong; Wang, Xianbo

doi:10.1016/j.phymed.2021.153784

Cited by 14 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since January 2020, the YDJDG has been used to treat patients with COVID-19 at the Beijing Ditan Hospital. Our previous clinical study confirmed that, compared with lopinavir-ritonavir treatment or routine treatment, YDJDG could hasten the recovery period in patients with COVID-19 by shortening the SARS-CoV-2 nucleic acid shedding time, the mean duration of fever, and exudative pulmonary lesions (Liu et al, 2020a;Feng et al, 2022). We also revealed that one of the mechanisms by which YDJDG can shorten the course of COVID-19 and delay its progression is the inhibition of inflammation by targeting the NF-κB pathway (Feng et al, 2022).…”

Section: Introductionmentioning

confidence: 59%

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Feng

Liu

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to control, and patients with high-risk factors prone to progress rapidly.Purpose: To evaluate YDJDG’s efficacy in treating patients with the Omicron variant BA.2 with high-risk factors and compared it with that of Paxlovid.Methods: A total of 257 patients who fulfilled the inclusion criteria were allocated to the YDJDG (115 cases), Paxlovid (115 cases), and control (27 cases) groups. A Cox regression model was used to analyze the independent factors affecting the shedding time of nucleic acid in 14 days. Propensity score matching (PSM) was used to match the characteristics of individuals in the three groups, while the Kaplan-Meier method was used to compare the shedding proportion of nucleic acids.Results: Cox analysis showed that the vaccine booster (p = 0.006), YDJDG treatment (p = 0.020), and Paxlovid treatment (p < 0.0001) were independent predictors of nucleic acid shedding at 14 days. The median recovery time was 11.49 days in the YDJDG group, 10.21 days in the Paxlovid group, and 13.93 days in the control group. After PSM (3:1), the results showed that the nucleic acid shedding time of the YDJDG group (n = 53) was 2.47 days shorter than that of the control group (n = 21) (p = 0.0076), while the Paxlovid group (n = 44) had a 4.34 days shorter than that of the control group (n = 17) (p < 0.0001). After PSM (1:1), YDJDG and Paxlovid (76 pairs) were also analyzed. In the YDJDG group, nucleic acid shedding time was 1.43 days longer than that observed in the Paxlovid group (p = 0.020). At 10 and 14 days, the Paxlovid group showed a significant difference in the nucleic acid shedding proportion compared with the control group (p = 0.036, p = 0.0015). A significant difference was also observed between the YDJDG and control groups (p = 0.040) at 14 days.Conclusion: As a safe and convenient oral drug, YDJDG can be used as an alternative to antiviral therapy for such patients.

show abstract

Section: Introductionmentioning

confidence: 59%

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Feng

Liu

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The traditional Chinese medicine, Shufeng Jiedu Capsule (SFJDC), is a herbal formulation of eight medicinal plants ( Ephedrae Herba, Gypsum Fibrosum, Mori Cortex, Scutellariae Radix, Lepidii Semen, Lonicerae Japonicae Flos, Scrophulariae Radix, Moutan Cortex, Rehmanniae Radix, Atractylodis Macrocephalae Rhizoma, and Cimicifugae Rhizoma ) and is a commonly used antiviral and anti-inflammatory drug in China ( Feng et al, 2022 ; Xia et al, 2018 , 2021 ). Evidence has shown that SFJDC is rich in flavonoids mainly quercetin and resveratrol with a concentration of about 0.18% and 0.154% respectively ( Xia et al, 2018 ).…”

Section: Herbal Medications and Natural Products In The Management Of...mentioning

confidence: 99%

“…A clinical study reported that a combination of standard antiviral therapy and oral supplementation with 0.2 ml SFJDC extract per 10 g body weight once daily for 4 days reduced the clinical recovery time as well as the duration of cough and fatigue in COVID-19 patients compared to the groups with the standard therapy only ( Xia et al, 2021 ). Moreover, a recent mechanistic study reveals that three times daily supplementation with 12 g or 24 g SFJDC granules exerts an anti-inflammatory effect in COVID-19 patients by suppressing some genes involved in the nuclear factor kappa B (NF-κB) signaling and the altered genes are mainly the targets of three of the bioactive components of SFJDC (quercetin, kaempferol, and luteolin) ( Feng et al, 2022 ). According to the study, molecular docking experiments reveal that the ligands of three compounds had strong interactions with NF-κB, p65, and IκBα ( Feng et al, 2022 ).…”

Section: Herbal Medications and Natural Products In The Management Of...mentioning

confidence: 99%

“…Moreover, a recent mechanistic study reveals that three times daily supplementation with 12 g or 24 g SFJDC granules exerts an anti-inflammatory effect in COVID-19 patients by suppressing some genes involved in the nuclear factor kappa B (NF-κB) signaling and the altered genes are mainly the targets of three of the bioactive components of SFJDC (quercetin, kaempferol, and luteolin) ( Feng et al, 2022 ). According to the study, molecular docking experiments reveal that the ligands of three compounds had strong interactions with NF-κB, p65, and IκBα ( Feng et al, 2022 ). It is noteworthy that although there is dearth of clinical evidence on the antidiabetic role of SFJDC, some of its bioactive components have been evaluated as potential anti diabetic in humans.…”

Section: Herbal Medications and Natural Products In The Management Of...mentioning

confidence: 99%

See 1 more Smart Citation

Herbal medications and natural products for patients with covid-19 and diabetes mellitus: Potentials and challenges

Yusuf

Zhang

et al. 2022

Phytomedicine Plus

View full text Add to dashboard Cite

“…2020 ;Yu H. Y. et al, 2020;Chen et al, 2020b;Xiao Q. et al, 2020;Ai Z. Z. et al, 2020;Zhang N. et al, 2020;Lan et al, 2020;Li, 2020;Liu et al, 2020;Xin et al, 2020;Yao et al, 2020;Zeng et al, 2020;Zhang L. H. et al, 2021;Wang Q. L. et al, 2021;Shi et al, 2021;Sun S et al, 2021;Feng et al, 2022) (Tian et al, 2020; enrolled 12,414 mild or moderate patients (male: 48.11%), with a mean age of 54.53 years. Fourteen OBs were published in Chinese (1 registered prospectively ) and 10 were published in English (4 registered prospectively (Tian et al, 2020;Xin et al, 2020;Shi et al, 2021)).…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies

Zhu

Tian

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) is still a pandemic globally, about 80% of patients infected with COVID-19 were mild and moderate. Chinese herbal medicine (CHM) has played a positive role in the treatment of COVID-19, with a certain number of primary studies focused on CHM in managing COVID-19 published. This study aims to systematically review the currently published randomized controlled trials (RCTs) and observational studies (OBs), and summarize the effectiveness and safety of CHM in the treatment of mild/moderate COVID-19 patients.Methods: We searched 9 databases up to 19 March 2022. Pairs of reviewers independently screened literature, extracted data and assessed risk of bias. For overall effect, we calculated the absolute risk difference (ARD) of weighted averages of different estimates, and certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) system.Results: We included 35 RCTs and 24 OBs enrolling 16,580 mild/moderate patients. The certainty of evidence was very low to low. Compared with usual supportive treatments, most effect estimates of CHM treatments were consistent in direction. CHMs presented significant benefits in reducing rate of conversion to severe cases (ARD = 99 less per 1000 patients in RCTs and 131 less per 1000 patients in OBs, baseline risk: 16.52%) and mortality (ARD = 3 less per 1000 patients in RCTs and OBs, baseline risk: 0.40%); shortening time to symptom resolution (3.35 days in RCTs and 2.94 days in OBs), length of hospital stay (2.36 days in RCTs and 2.12 days in OBs) and time to viral clearance (2.64 days in RCTs and 4.46 days in OBs); increasing rate of nucleic acid conversion (ARD = 73 more per 1000 patients in OBs, baseline risk: 16.30%). No serious adverse reactions were found and the differences between CHM and usual supportive care were insignificant.Conclusion: Encouraging evidence showed that CHMs were beneficial in treating mild or moderate patients. CHMs have been proved to possess a safety profile that is comparable to that of usual supportive treatment alone. More rigorously designed clinical trials and mechanism studies are still warranted to further confirm the present findings.

show abstract

Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway

Cited by 14 publications

References 19 publications

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Herbal medications and natural products for patients with covid-19 and diabetes mellitus: Potentials and challenges

Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies

Contact Info

Product

Resources

About